Log In
BCIQ
Print this Print this
 

Dutrebis, lamivudine/raltegravir (MK-0518B)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionFixed-dose combination of 150 mg lamivudine, a nucleoside analog reverse transcriptase inhibitor (NRTI), and 300 mg raltegravir, an HIV integrase inhibitor
Molecular Target HIV integrase ; Viral polymerase
Mechanism of ActionHIV integrase inhibitor; Nucleoside analog reverse transcriptase inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentApproved
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection in adults, adolescents, and children 6 years of age and older
Regulatory Designation EU - Standard Review (Treat HIV-1 infection in adults, adolescents, and children 6 years of age and older)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today